Diabetes

Carl "Chip" Lavie, MD, author of the original book titled, "The Obesity Paradox" explains the paradox of metabolic health in the obese, how it wanes, and an essential element to maintain it.

Waist circumference measures, complementary antihypertensives, appropriate exercise levels for T2D patients--test what you know about cardiometabolic risk and management.

The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.

Diabetes is a primary risk factor for atherosclerotic cardiovascular disease. Find out how well you know the guideline recommendations for reducing that risk with the first of 4 quizzes.

According to a new study, adults with T2D who were hospitalized with COVID-19 in northern Italy had a lower mortality rate when treated with sitagliptin.

The association of vascular dementia with T2D is stronger than that of nonvascular or Alzheimer dementia, according to a study presented at EASD.

What do clinical guidelines from diabetes, cardiology, and endocrinology associations have in common? A case study quiz with an evidence-based answer explains.

Empagliflozin is now in FDA fast-track development for prevention of hospitalization for HF and reduced all-cause mortality in patients, with/without diabetes, post-AMI.

A new research article found moderate and heavy alcohol intake were associated with hypertension in patients with type 2 diabetes.

A new research article showed that after 1 year of weight loss intervention, 46% of patients with type 2 diabetes achieved remission.

The risk of having a CVD-related event is increased by 21% for every 1% increase in usual A1c >7% in patients with type 2 diabetes, a new study finds.

Refresh your memory on findings from the EMPA-REG OUTCOME, CANVAS, CREDENCE, and DECLARE-TIMI cardiovascular outcomes trials on SGLT2 inhibitors.

Insulin affordability is an ongoing discussion topic for patients with diabetes and their care providers. The already difficult issue has been further compounded by the ongoing COVID-19 pandemic.

In patients with obesity and type 2 diabetes, metabolic improvements were similar after weight loss induced by surgery or a low-calorie diet.

VIDEO: Obesity is a chronic, relapsing disease that threatens to neutralize, even reverse, years of progress in reducing CVD-related death. Ted Kyle, RPh, explores.

Jorge Plutzky, MD, director of the Preventive Cardiology Program at Brigham and Women's Hospital, discusses the insidious role diabetes plays in cardiovascular disease.

SGLT2 inhibitors and GLP-1 receptor agonists are changing the type 2 diabetes treatment paradigm. We summarize the most recent data here and offer guidance on patient benefits.

The physiology of obesity makes weight loss, by itself, unlikely to successfully treat the chronic disease of obesity. What does this mean for primary care clinical strategies?

Meet 2 type 2 diabetes patients on multiple antihyperglycemics but still not meeting the ADA recommended A1c goal of 7%. What are the next best steps?

Metabolic and bariatric surgery are deemed "elective," along with cosmetic procedures, and still widely postponed. "Resume these life-saving procedures, now," says the ASMBS.

Roux-en-Y gastric bypass remains the gold standard of bariatric surgery. Obesity and nutrition expert Caroline Apovian, MD, explains why and how it differs from the 3 other types of weight loss surgery.

Three patients with type 2 diabetes in different stages of life and disease all require insulin management for A1c control.

VIDEO: Kieran Docherty, MBChB, discusses results of the DAPA-HF analysis on the impact of background T2D therapy on clinical outcomes in patients with T2D and HFrEF.

ADA 2020. Average A1c for a recent young cohort with type 2 diabetes was 8.5%, according to research presented at the ADA Virtual Scientific Sessions.

New data from the Diabetes Prevention Outcomes Study shows persistent reduction of type 2 diabetes development over 22-year average follow-up.

VIDEO: Silvio Inzucchi, MD, discusses results of a prespecified analysis of the DAPA-HF trial, which found that dapagliflozin reduced new onset diabetes by 32% in patients with heart failure.

ADA 2020: Glycemic control was worse for black patients who experienced hurried interaction with healthcare providers than for those who did not, a new study reports.

ADA 2020. Improvement in glycemic control among US veterans was seen across 5 study sites and was sustained at 18 months after study initiation, says study reported at the ADA 80th Virtual Scientific Sessions.

ADA 2020. An investigational once-weekly insulin proved comparable in safety and efficacy to traditional once-daily insulin glargine in findings presented at the ADA 80th Annual Virtual Scientific Sessions.

ADA 2020. Dapagliflozin reduced new onset type 2 diabetes in patients with heart failure with reduced ejection fraction, according to a study released today at the ADA 80th Virtual Scientific Sessions.